Loading clinical trials...

The Effect of GCSF in the Treatment of ALS Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

The Effect of GCSF in the Treatment of ALS Patients

The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013

NCT01825551•Tehran University of Medical Sciences

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age between 18 and 85
•definite or probable ALS according to revised El Escorial criteria
•maximum 2 years from initiation of symptoms to study entry
•mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r)

Exclusion Criteria

•familial ALS
•pregnancy or lactation
•myeloproliferative or hematologic disorders
•active immunological disease
•liver or renal or heart disease
•HIV positive
•significant cognitive disorder
•hypersensitivity to GCSF

Locations (1)

Iranian Neurology Research Center of Tehran University of Medical Sciences

Tehran, Tehran Province, Iran

Key Dates

Start Date

November 1, 2012

Primary Completion Date

November 1, 2013

Completion Date

November 1, 2013

Last Updated

November 13, 2013

Enrollment

ACTUAL participants

Conditions

Amyotrophic Lateral Sclerosis

Interventions

Granulocyte Colony Stimulating Factor

DRUG

Placebo

DRUG

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003

Amyotrophic Lateral Sclerosis

View study

RECRUITING

Intermuscular Coherence as a Biomarker for ALS

NCT05104710

Amyotrophic Lateral Sclerosis

View study

RECRUITINGNA

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

NCT07357428

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of GCSF in the Treatment of ALS Patients

Inclusion Criteria

Exclusion Criteria

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Intermuscular Coherence as a Biomarker for ALS

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

UPenn Observational Research Repository on Neurodegenerative Disease

Control Cohort CTRL COH

Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles